Skip to content
Catalyst

PapersPMID:34588374

A Randomized, Double-Blind Comparison Study of Royal Jelly to Augment Vascular Endothelial Function in Healthy Volunteers.

Journal of atherosclerosis and thrombosis2022The record ↗

findings
2
compound
1
endpoints
2
no difference found
1
  1. Finding, moderate evidencelowersAlanine aminotransferase
  2. Finding, moderate evidenceno difference foundGlycated haemoglobin (HbA1c)
Study, every finding
RCT · 4 weeks
Dose studied, every finding
690 mg dried royal jelly (equivalent to 2040 mg fresh royal jelly) as tablets daily for 4 weeks
Population, every finding
Healthy Japanese volunteers aged 20–60 without diabetes, hypertension or dyslipidaemia, non-smokers
  • “The percentage relative changes in ALT and γGT were significantly lower in the royal jelly group than in the placebo group (ALT: −6.06%±22.2% vs. 11.6%±46.5%, P=0.02; γGT: −3.45%±17.8% vs. 4.62%±19.4%, P=0.045) (Table 2).”

What did not

  • “The percentage relative changes in fasting blood glucose and hemoglobin A1c were not significantly different between the two study groups (placebo vs. royal jelly: fasting blood glucose, −0.17%±7.9% vs. −0.08%±7.6%, P=0.95; hemoglobin A1c, −0.15%±2.0% vs. −0.09%±2.3%, P=0.91).”

Study record

Design
randomised controlled trial
Species
human
Population
Healthy Japanese volunteers aged 20-60 years without diabetes, hypertension or dyslipidaemia, single centre (Kumamoto University); oral royal jelly tablet 690 mg/day (dried royal jelly, equivalent to 2040 mg fresh royal jelly) versus placebo tablet for 4 weeks
Participants
88
Comparator
placebo
Duration
28 days
Endpoints measured
72